摘要
目的:观察奈达铂联合多西紫杉醇一线治疗复发/晚期非小细胞肺癌(NSCLC)的疗效及急性不良反应。方法:收治既往未行化疗(辅助或新辅助化疗除外)及分子靶向治疗的复发或晚期NSCLC患者85例,随机分为两组,全组可评估疗效的73例:研究组(奈达铂联合多西紫杉醇)36例,对照组(顺铂联合多西紫杉醇)37例。比较两组的近期有效率、中位无进展生存期(PFS)及急性不良反应。结果:研究组和对照组有效率分别为44.4%(16/36)和45.9%(17/37),P=0.098;PFS分别为5.2和5.1个月,P=0.655;Ⅲ+Ⅳ度消化系统急性毒性,恶心及呕吐分别为2.8%(1/36)和27.0%(10/37),P=0.004;食欲下降分别为5.6%(2/36)和32.4%(12/37),P=0.022;肾毒性分别为0(0/36)和5.4%(2/37),P=0.027;血小板下降为11.1%(4/36)和2.7%(1/37),P=0.011。>4个周期为72.2%(26/36)和45.9%(17/37),P=0.032。结论:奈达铂联合多西紫杉醇一线治疗NSCLC,疗效与标准方案相当,但患者对该方案治疗的顺应性较好。
OBJECTIVE： To observe the effect and acute toxicity of the regime of nedaplatin combined with docetaxel in the first-line treatment of recurrent or advanced non-small cell lung cancer （NSCLC）. METHODS： Totally 85 cases of NSCLC which hadn＇t previously treated by chemotherapy （besides adjuvant chemotherapy or neo-adjuvant chemotherapy） or molecular targeted therapy entered this study . All patients were randomly divided into two groups and then 73 cases can be evaluated in all： 36 in the group of study, the regime of nedaplatin combined with docetaxel, and 37 in the one of control, the regime of cisplatin combined with docetaxel. The remission rate （RR）, median progression-free survival （PFS） and acute toxicity were compared between two groups. RESULTS： In the study group or the control group： the RR was 44.4%（16/36） vs 45.9%（17/37）, （P=0. 098）, respectively; PFS was 5.2 vs 5.1 months （P=0. 655）, respectively; the acute toxicity of III ＋IV degree of nausea and vomit was 2.8%（1/36） vs 27.0%（10/37）, （P=0. 004）, respectively, and anorexia was 5.6%（2/36） vs 32.4%（12/37）, （P=0.022）, respectively; renal toxicity was O（O/36）vs 5.4% （2/37）, （P=0.027）, respectively; thrombocytopenia was 11.1% （4/36）vs 2.7% （1/37）, （P=0.011）, respectively; and then, the number of chemotherapy cycle which was more than four, was 72.2%（26/36） vs 45.9% （17/37）, （P=0. 032）, respectively. CONCLUSION： The effect of the regime of nedaplatin and docetaxel is equal to, but the compliance of patient is better than the standard regime in the first-line treatment of recurrent or advanced NSCLC.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2012年第7期525-528,共4页
Chinese Journal of Cancer Prevention and Treatment
基金
瑞安科技局科技计划项目(201002087)
关键词
癌
非小细胞肺
奈达铂
多西紫杉醇
carcinoma, non-small cell lung
nedaplatin
docetaxel
